Literature DB >> 3136816

Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease.

M Greaves1, R G Malia, A Milford Ward, J Moult, C M Holt, N Lindsey, P Hughes, M Goodfield, N R Rowell.   

Abstract

Plasma levels of the factor VIII complex (von Willebrand factor antigen, factor VIII coagulant and ristocetin co-factor) were measured in 28 patients with systemic sclerosis. Elevated von Willebrand factor antigen was found in 12 patients overall and in 10 of 16 patients characterized by severe extensive visceral disease, with a resulting positive correlation between the extent of visceral involvement and the plasma level of von Willebrand factor antigen (r = 0.60, p less than 0.001). Factor VIII coagulant and ristocetin co-factor levels, however, frequently failed to parallel the increases of von Willebrand factor antigen, supporting the view that these increases were due to in vivo endothelial damage. The findings suggest that vascular damage is an important aspect of the visceral lesions of systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136816     DOI: 10.1093/rheumatology/27.4.281

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  11 in total

1.  Raised concentrations of von Willebrand factor antigen in systemic sclerosis.

Authors:  A D Blann; K J Illingworth; M I Jayson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

3.  Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.

Authors:  S Furukawa; S Yasuda; O Amengual; T Horita; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

5.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

6.  Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis.

Authors:  C M Holt; N Lindsey; J Moult; R G Malia; M Greaves; A Hume; N R Rowell; P Hughes
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

7.  Clinical significance of von Willebrand factor in patients with adult dermatomyositis.

Authors:  Toshiyuki Komiya; Nobuo Negoro; Kyoko Kondo; Katsuyuki Miura; Yoshio Hirota; Junichi Yoshikawa
Journal:  Clin Rheumatol       Date:  2004-11-23       Impact factor: 2.980

8.  Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.

Authors:  M Vayssairat; N Baudot; N Abuaf; C Johanet
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

9.  Vascular involvement in systemic sclerosis (scleroderma).

Authors:  Debendra Pattanaik; Monica Brown; Arnold E Postlethwaite
Journal:  J Inflamm Res       Date:  2011-07-26

10.  Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

Authors:  A Scheja; A Akesson; P Geborek; M Wildt; C B Wollheim; F A Wollheim; U M Vischer
Journal:  Arthritis Res       Date:  2001-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.